MOSCOW, November 25. /TASS/. The Federal Medical and Biological Agency (FMBA) could begin using its breakthrough cancer vaccines on patients as early as next year, the agency’s head Veronika Skvortsova has announced.

"We have nearly completed a three-year cycle of testing this vaccine. With the adoption of the law on personalized medicines this year, we hope to begin using it on patients as early as next year," Skvortsova said during a meeting with Russian President Vladimir Putin.

She noted that parallel studies are being conducted on vaccines for various cancers, including melanoma, skin cancer, and glioblastoma, a malignant brain tumor.

The agency head stated that a cluster of four FMBA centers has developed technology to identify mutations responsible for tumors in individual patients. "This allows the selection of peptide fragments that act as signals for a specific person’s immune system," Skvortsova explained.

Specialists have also developed a technology to synthesize these peptides, which activate the immune system and target the tumor. Vaccines using these peptides as active ingredients are now being created. In experiments on animals with highly malignant intestinal adenocarcinoma, the size of the tumors was reduced by 75-80%, saving their lives.